Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 4/20 | 0.62 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.62 |
| ▸ | FAAH | O00519 | 13/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.53 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5221042 | 0.81 | FAAH (0.70) | S1PR1S1PR3FAAHGAAL3MBTL1 | |
| SCHEMBL5218334 | 0.81 | FAAH (0.70) | S1PR1S1PR3FAAHGAAL3MBTL1 | |
| SCHEMBL5215792 | 0.81 | FAAH (0.70) | S1PR1S1PR3FAAHGAAL3MBTL1 | |
| SCHEMBL2089631 | 0.81 | FAAH (0.70) | S1PR1S1PR3FAAHGAAL3MBTL1 | |
| SCHEMBL5223000 | 0.81 | FAAH (0.70) | S1PR1S1PR3FAAHGAAL3MBTL1 | |
| SCHEMBL5221933 | 0.81 | FAAH (0.70) | S1PR1S1PR3FAAHGAAL3MBTL1 | |
| SCHEMBL14456478 | 0.81 | S1PR1 (0.77) | S1PR1S1PR3FAAHSPHK1 | |
| SCHEMBL4984266 | 0.81 | S1PR1 (0.54) | S1PR1S1PR3FAAHGAAL3MBTL1 | |
| SCHEMBL14521775 | 0.80 | S1PR1 (0.68) | S1PR1S1PR3FAAHGAAL3MBTL1 | |
| SCHEMBL14521759 | 0.80 | S1PR1 (0.68) | S1PR1S1PR3FAAHGAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1918287-A2 | LPA receptor agonists and antagonists and methods of use | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2008-05-07 | — | — | EP | disclosed |
| EP-1263752-B1 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIV TENNESSEE RES CORP (US) | 2007-12-05 | — | — | EP | disclosed |
| US-20050261252-A1 | LPA receptor agonists and antagonists and methods of use | MILLER DUANE D | 2005-11-24 | — | — | US | disclosed |
| US-6875757-B2 | For therapy of cancer, enhancing cell proliferation, and wound | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2005-04-05 | — | — | US | disclosed |
| US-20030130237-A1 | LPA receptor agonists and antagonists and methods of use | MILLER DUANE D (US) | 2003-07-10 | — | — | US | disclosed |
| US-20030027800-A1 | LPA receptor agonists and antagonists and methods of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261252-A1 | LPA receptor agonists and antagonists and methods of use | LPAR1, LPAR2, LPAR3 | S1PR1 25/4885S1PR3 31/4885FAAH 141/4885 |
| US-20030027800-A1 | LPA receptor agonists and antagonists and methods of use | LPAR1, LPAR2, LPAR3 | S1PR1 25/4885S1PR3 31/4885FAAH 141/4885 |
| US-20030130237-A1 | LPA receptor agonists and antagonists and methods of use | LPAR1, LPAR2, LPAR5 | S1PR1 16/4885S1PR3 24/4885FAAH 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.